Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Show more

3060 Pegasus Park Drive, Dallas, TX, 75247, United States

Biotechnology
Healthcare

Market Cap

674.7M

52 Wk Range

$4.90 - $35.80

Previous Close

$34.43

Open

$34.50

Volume

105,712

Day Range

$33.00 - $34.82

Enterprise Value

597.7M

Cash

76.96M

Avg Qtr Burn

-16.47M

Insider Ownership

2.36%

Institutional Own.

67.17%

Qtr Updated

12/31/25